Agios Pharmaceuticals (AGIO) announced that the Emirates Drug Establishment, EDE, of the United Arab Emirates, UAE, has approved Pyrukynd, an oral pyruvate kinase activator, for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. With this approval, Pyrukynd becomes the only medicine approved in the UAE for this patient population.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals Signals Confident Path After AQVESME Win
- Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook
- Buy Rating Backed by Strong Q4 Execution, Early Aqvesme Momentum, and Multi-Asset Clinical Catalyst Upside
- Agios Pharmaceuticals files automatic mixed securities shelf
- Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating